
Need Support?

Georgia laboratories billing Medicare for genetic sequencing must follow Palmetto GBA’s MolDX requirements before submitting claims under Jurisdiction J. Unlike commercial prior authorization, the MolDX Technical Assessment evaluates the laboratory test itself and requires supporting evidence of analytical validity, clinical validity, and clinical utility. Approved tests receive a unique DEX Z-Code that must be correctly linked to the claim and supported by applicable Medicare coverage policies.
However, Z-Code approval alone does not guarantee payment; the patient’s diagnosis and testing circumstances must also align with current LCD and Local Coverage Article requirements. For Georgia labs offering NGS panels, germline testing, or other molecular diagnostics, accurate Technical Assessment documentation, current coding rules, and front-end claim validation can help prevent systemic denials and protect Medicare revenue.
If your laboratory bills Medicare patients in Georgia, you already know that getting paid for genetic sequencing isn’t an easy task. The rules are strict, the systems are automated, and a single misstep can trigger a cascade of denials before a human reviewer ever looks at your claim.
Under Palmetto GBA, the Medicare Administrative Contractor (MAC) for Jurisdiction J, genetic tests don’t go through a standard prior authorization. Instead, they run through the Molecular Diagnostic Services (MolDX) program, which has its own rigorous Technical Assessment (TA) process, registry, and unique identifiers called DEX Z-Codes.
This guide breaks down exactly what your revenue cycle management (RCM) team needs to know in 2026: how the TA process works, which forms to use, how to build clean claims, and how to keep automated denials off your AR aging report. We’ll also discuss how expert laboratory billing services in Georgia help with all that.
The MolDX program is the coverage and payment framework that governs molecular diagnostic tests (MDTs) for Medicare patients under Palmetto GBA. It applies to labs in states across Jurisdiction J (Alabama, Georgia, and Tennessee), among other jurisdictions. But many Georgia labs, especially those running next-generation sequencing (NGS) panels, experience claim denials because they don’t fully understand how MolDX works.
Here’s the core thing to understand: MolDX replaces traditional prior authorization. Commercial payers like Anthem BCBS or Ambetter require a patient-specific pre-auth before you run a test. Palmetto GBA doesn’t work that way. Instead, your lab must get the test itself approved before you can ever bill it to Medicare, regardless of the patient.
That’s a big deal. It means the denial is systematic. And fixing it requires understanding the full pipeline from test registration to claim submission.
| Feature | Commercial Prior Authorization | Palmetto GBA MolDX Technical Assessment |
|---|---|---|
| Approval Level | Per patient, per episode of care | Per laboratory test (one-time approval) |
| Submission Timing | Before the test is performed | Before the test is ever marketed or billed |
| Identifier Used | Authorization number (e.g., from AIM/Carelon) | DEX Z-Code appended to the claim |
| Core Documentation | Patient chart notes, medical necessity for that patient | Validation dossier covering analytical and clinical validity, plus clinical utility |
| RCM Impact of Failure | One patient's claim was denied (preventable with pre-auth) | Every single claim for that CPT code gets auto-rejected |
This is the hardest pillar to clear. It’s where most dossiers fall apart. Clinical utility means your test doesn’t just find something; it changes what the physician does. Does it match the patient to an FDA-approved targeted therapy? Does it rule out an unnecessary intervention?
If the results sit in a chart and never alter the clinical path, the test lacks utility in MolDX’s eyes, and it won’t get approved. All three pillars must be addressed before Palmetto GBA will issue a DEX Z-Code.
Submit your Technical Assessment through the DEX Diagnostics Exchange (DEX), the official registry mandated by Palmetto GBA for all MolDX test registrations.
Here’s the basic process:
If your lab sends specimens to a reference laboratory, you’ll also need to set up a Z-Code sharing agreement through the DEX portal. Without that agreement in place, even a fully approved test can trigger a denial because the billing lab doesn’t have authorization to use the Z-Code.
Palmetto GBA doesn’t accept a one-size-fits-all validation summary. Each test type has a specific, structured worksheet, and submitting the wrong form is an instant denial.
Here’s a quick-reference guide by test type:
| Test Category | Applicable LCD | Required TA Form |
|---|---|---|
| Solid Tumor NGS (hot-spot and CGP panels) | LCD L38045 | SOM-PF-004 |
| Myeloid and Hematopoietic Malignancies (AML, MDS, MPN) | LCD L38047 | SOM-PF-005 |
| Inherited Cancer Testing (germline) | Germline testing guidelines | GER-PF-006 |
| Inherited Germline Testing (non-cancer) | Germline testing guidelines | GER-PF-008 |
| Pharmacogenomics (PGx) | PGx coverage policy | PGX-PF-007 |
| Minimal Residual Disease (MRD) | MRD coverage policy | MRD-PF-016 |
| Molecular Risk Stratification | MRS coverage policy | MRS-PF-020 |
| Syndromic Infectious Disease Panels | Infectious disease MDT policy | MID-PF-019 |
| Solid Organ Allograft Rejection | Allograft policy | ALLO-CQ-003 + ALLO-PF-009 |
Important note: Always download worksheets directly from Palmetto GBA’s portal before submitting. Forms are updated periodically, and using an outdated version, even by a quarter, can trigger an automatic administrative denial. Also check DEX Official Forms Checklist and Matrix, a useful companion tool that maps each test methodology to the correct somatic or germline form.
Here’s something labs often miss: getting a DEX Z-Code doesn’t mean every claim gets automatically reimbursed. That Z-Code just helps your claim pass through the first step. Once your claim is in adjudication, Palmetto GBA’s system checks it against Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs) to confirm that the patient’s diagnosis supports medical necessity for that specific test.
The most important billing reference document is LCA A56853 (Billing and Coding: MolDX: Molecular Diagnostic Tests). This article maps:
If you’re billing CPT 81445 (solid tumor NGS) but submitting an ICD-10 code that isn’t listed in the active LCA for that CPT, your claim is automatically denied for medical necessity, even with a valid Z-Code attached.
The fix? Monitor the CMS Medicare Coverage Database (MCD) regularly, or at least every month, for any updates to active LCDs and LCAs that govern your test menu.
You’ve got your Z-Code. Your ICD-10 codes are aligned. Now comes the part that trips up even experienced billers: putting the Z-Code in exactly the right place on the claim.
Palmetto GBA’s adjudication system is fully automated, which means placement matters as much as the code itself. A Z-Code in the wrong field is just as bad as a missing one.
Whether you submit claims in-house or outsource claim submission to a reliable billing partner, such as TransLabs, you must master the use of DEX Z-Code on your lab claims for correct claims and secured reimbursement.
Billing genetic sequencing to Medicare in Georgia isn’t complicated once you understand how the system is actually built. The MolDX Technical Assessment isn’t a hurdle. It’s the foundation. Get it right, and your claims flow cleanly. Skip a step or use the wrong form, and your entire billing pipeline for that test shuts down automatically.
The key takeaways are simple:
If your lab is running NGS panels, pharmacogenomics tests, or germline sequencing for Georgia Medicare patients and you’re still dealing with high denial rates, it’s time to fix your front-end process, whether it’s in your TA documentation or your claim-building workflow. Getting that front-end process right is what turns a struggling billing department into one that consistently collects what it earns.